FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

Senate: Kaléo’s Naloxone Price Hike Cost Taxpayers Millions

Nov. 26, 2018
A A

Kaléo’s massive, artificially inflated price hikes for its naloxone auto-injector Evzio have cost taxpayers more than $142 million over the past four years, says a new Senate report.

The Senate Homeland Security and Governmental Affairs Committee’s investigations subcommittee said the company exploited the nation’s opioid crisis by raising the price of its opioid overdose reversal treatment by more than 600 percent.

Congressional researchers found that Kaléo ignored recommendations from industry experts to set the tab at $250 or $300 per unit and offer discounts and rebates — and instead initially settled on $575 per unit, which it upped to $3,750, and, less than a year later, increased to $4,100 as part of a new distribution model.

View today's stories